Additional Collaboration Sample Clauses

Additional Collaboration. Novatel Wireless and Intel will engage in the following technical collaboration: a) Novatel Wireless, in consultation with and support from Intel, will provide all personnel, resources, and IP to complete the work described in the statement of work attached in Exhibit J-1, also referred to as Phase 1b. The parties recognize that they have not set forth in full detail all technical aspects of the statement of work attached in Exhibit J-1. Upon execution of this agreement, the parties will complete this statement in reasonable detail. If the parties are unable for any reason to agree on such details within sixty (60) calendar days following the effective date, Novatel Wireless will in good faith perform the work as presently described with a goal of making Novatel Wireless technology work as well on platforms targeted in the statement of work attached as Exhibit J-1 as on any other silicon, board or system architecture. b) Novatel Wireless presently intends to perform the work described in the statements of work set forth in Exhibits J-2 also referred to as Phase 2. The parties recognized that they have reached full agreement upon the advisability or the scope of this work. Upon execution of this agreement, Novatel Wireless will in good faith agree with Intel on this scope of this work. If the parties are unable for any reason to agree on such details within ninety (90) calendar days following the effective date, Novatel Wireless will in good faith perform the work as presently described with a goal of making Novatel Wireless technology for Software Reconfigurable Radios work on Intel Silicon. c) Assuming the success of Phase 2 technology development (as mutually defined and agreed to by both companies), the productization of such technology will be undertaken as set forth in Exhibit J-3 also referred to as Phase 2b. The parties recognized that they have reached full agreement upon the advisability or the scope of this work - given that the Phase 2 technology achieves its performance and cost targets. Upon execution of this agreement, Novatel Wireless will in good faith agree with Intel on the next level of details for this phase. If the parties are unable for any reason to agree on such details within 365 calendar days following the effective date, the high level terms set forth in the current exhibit will continue to remain in effect - unless mutually agreed to in writing between the two companies.
AutoNDA by SimpleDocs
Additional Collaboration. Within [***] after the Effective Date, the Parties will discuss the [***].
Additional Collaboration. The parties anticipate that there may be additional opportunities for collaboration beyond what is described in this Agreement, and which may be generally expected of two public agencies operating within the same geographic area. It is not the purpose of this Agreement to modify or to formalize interactions that are within the normal course and scope of business between the two agencies or collaboration which may typically occur without an interlocal agreement in place. Such collaboration, which is not governed by this Agreement, may include but is not limited to, authoring letters of support for funding, participating in meetings with elected and agency officials, traveling to advocate for the parties in Washington DC or Olympia, and more.
Additional Collaboration. Party shall promptly provide to the other Party all data, materials and other information, and shall promptly take all such other actions, as may be reasonably requested by the other Party from time to time in order to perform its obligations hereunder and comply with all Laws applicable to the matters addressed in this Agreement. ARTICLE IIIEach Party shall cooperate with the other Party’s reasonable requests in responding to or resolving any complaint, investigation, inquiry or review initiated by a governmental agency, or otherwise relating to the Product or the services provided by either Party as described in this Agreement. Each Party shall cooperate with the reasonable request of any insurance company providing protection to either Party in connection with the foregoing.
Additional Collaboration. The Parties shall exercise good-faith negotiations to enter into a separate collaboration aimed at the further development and commercialization of one or more therapeutics encompassing or employing an siRNA that is deliverable to the posterior pole of the eye which may be administered by systemic application for pharmaceutical use in humans (the “Systemic siRNA”). The financial terms of the Systemic siRNA collaboration shall be consistent with and substantially similar to the provisions of Sections 7.1, 7.3, 7.4, 7.5 and 7.6(a) of this Agreement, after taking into account and considering the relevant market for the Systemic siRNA and its expected commercial success.
Additional Collaboration. If Producer wishes to terminate any Author, such Author shall retain any and all amounts paid, or due and payable, by Producer to such Author hereunder at the time of such termination. Notwithstanding anything to the contrary herein, each Author acknowledges that the Film is an established story, and that, inevitably, different individuals approaching the material contained in the Film may develop such material in ways that are similar, and even in some cases identical, to such Author’s development of material hereunder. Such Author further acknowledges and agrees that Producer and Owner are entitled to discuss the Film with third parties and obtain third party ideas and suggestions for developing material related thereto, and if Producer or Owner ultimately uses material that is the same as or similar to material which such Author creates, such Author shall not be entitled to any compensation or credit except in the limited situation in which the original material created by such Author hereunder rises to the level of being separately protectable under the United States Copyright Act of 1976 (as amended), taking into account material owned by the Owner (including, without limitation, the Film), material provided to such Author by other authors of or contributions to the Play, material provided to such Author by Producer, material in the public domain, scènes à faire and similar doctrines, and any other defense that would be available in a copyright infringement litigation. If such Author alleges that any such separately protectable material has been used and Producer agrees with such allegation, Producer and such Author shall negotiate in good faith to determine an appropriate payment and attribution, but in the event of a disagreement either as to liability or compensation, the arbitration provisions of paragraph 19 below shall apply and, without limiting the generality of the foregoing or the other provisions of paragraph 19 below, such Author, and anyone claiming by, through or under such Author, shall not be entitled to equitable relief, whether injunctive or otherwise, in connection with the use of any such separately protectable materials. In any event, Producer shall be entitled to continue with the development of the Play during negotiations and/or the pendency of any dispute with such Author being replaced.
Additional Collaboration. Upon execution of this MOU, individual institutions of NSHE may separately collaborate with the Secretary of Education in Tamaulipas, as well as Tamaulipas colleges and universities, to further develop and implement institution-specific programs and enter into agreements consistent with the intent, scope, and terms of this MOU.
AutoNDA by SimpleDocs

Related to Additional Collaboration

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!